Copyright
©The Author(s) 2004.
World J Gastroenterol. Dec 15, 2004; 10(24): 3634-3638
Published online Dec 15, 2004. doi: 10.3748/wjg.v10.i24.3634
Published online Dec 15, 2004. doi: 10.3748/wjg.v10.i24.3634
Table 1 Patients’ demographics
| Characteristic | |
| Age (yr) | |
| Median | 52 |
| Range | 18-76 |
| Sex | |
| Male (%) | 35 (70%) |
| Female (%) | 15 (30%) |
| ECOG Performance Status | |
| Grade 0 | 15 (30%) |
| Grade 1 | 21 (42%) |
| Grade 2 | 14 (28%) |
| Pretreatment | |
| Total | 39 (78%) |
| Surgical | 24 (48%) |
| Chemotherapy | 37 (74%) |
| Radiotherapy | 20 (40%) |
| Biotherapy | 8 (16%) |
| Two or more treatment | 31 (62%) |
| Tumor size (cm2) | |
| Median | 12.5 |
| Range | 1.43-360 |
- Citation: Lu W, Zheng S, Li XF, Huang JJ, Zheng X, Li Z. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: A pilot phase II clinical trial. World J Gastroenterol 2004; 10(24): 3634-3638
- URL: https://www.wjgnet.com/1007-9327/full/v10/i24/3634.htm
- DOI: https://dx.doi.org/10.3748/wjg.v10.i24.3634